NCT06432569View on ClinicalTrials.gov

Evaluation of Butyrate and Palmitoylethanolamide in IBS Patients (B/P3_1)

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 8, 2024

Primary Completion Date

July 7, 2025

Study Completion Date

July 7, 2025

Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
DIETARY_SUPPLEMENT

ButirBioma + PeaBioma

randomized in a 1:1 ratio to treatment Butir+Pea or treatment with Placebo for six weeks. After the first treatment period, there is a 14-day washout period.

DIETARY_SUPPLEMENT

Placebo

Placebo( 3+3 cps/die)

Trial Locations (1)

35128

Edoardo Vinvenzo Savarino, Padua

All Listed Sponsors
lead

University of Padova

OTHER

NCT06432569 - Evaluation of Butyrate and Palmitoylethanolamide in IBS Patients (B/P3_1) | Biotech Hunter | Biotech Hunter